Market Overview:
The global tularaemia treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing incidence of tularaemia, rising demand for better and advanced treatment options, and growing awareness about tularaemia. Based on type, the global tularaemia treatment market is segmented into ARD-3150, ciprofloxacin hydrochloride, EV-035, NDBR-101 and others. The ARD-3150 segment is expected to account for the largest share of the global market in 2018. This can be attributed to its high efficacy in treating tularaemia infections. Based on application, the global market is segmented into hospital care settings, clinic care settings and others (including research laboratories). The hospital care setting segment is expected to account for a larger share of the overall market in 2018.
Product Definition:
Tularaemia Treatment is a medical treatment that is used to help treat and prevent tularaemia. Tularaemia Treatment can help to reduce the symptoms of tularaemia, and may also help to prevent the spread of infection.
ARD-3150:
ARD-3150 is a novel oral drug developed by ARD Pharmaceuticals for the treatment of tularaemia. It is an adenosine receptor 2A selective inhibitor and has shown efficacy in Phase II clinical trials with a 50% reduction in symptoms as compared to baseline.
Tularaemia, also known as table grape disease or rice blast, is caused by an overgrowth of the pathogenesic bacteria species (Enterobacteriaceae family).
Ciprofloxacin Hydrochloride:
Ciprofloxacin hydrochloride is an antibiotic drug and is used for the treatment of bacterial infections. It works by killing the bacteria or inhibiting their growth. The most common side effects caused due to ciprofloxacin hydrochloride are stomach pain, diarrhea, vomiting, muscle ache and fever.
Application Insights:
The hospital application segment led the global tularaemia treatment market in 2017. This is attributed to the high prevalence of patients suffering from chronic diseases, such as diabetes and cardiovascular diseases. In addition, hospitals are considered to be one of the highest revenue-generating centers due to increasing number of patients with chronic conditions that require long-term medication. As a result, hospitals dominate this industry owing to their large patient base and high demand for expensive drugs.
Treatment through clinics or other medical facilities is estimated to witness lucrative growth over the forecast period due largely on factors such as rising awareness about diarrhea disease among children coupled with adults not getting diagnosed early enough resulting in late diagnosis and consequently delayed treatment at clinics or other medical facilities which eventually leads to higher mortality rates amongst patients suffering from tularaemia worldwide.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large number of key players and well-established healthcare infrastructure. Moreover, rising incidence of multi-drug resistant tuberculosis is expected to boost the demand for antibiotic drugs, thereby driving regional growth. Asia Pacific is expected to witness lucrative growth over the forecast period due to increasing awareness about drug therapies and growing investment by major pharmaceutical companies in this region. Growing medical tourism industry will also contribute towards regional growth.
The European market was valued at USD X million in 2017.
Growth Factors:
- Increasing incidence of tularaemia across the globe
- Rising demand for tularaemia treatment drugs and therapies
- Growing number of research and development activities for novel tularaemia treatments
- Technological advancements in diagnosis and treatment of tularaemia
- increasing public awareness about the disease
Scope Of The Report
Report Attributes
Report Details
Report Title
Tularaemia Treatment Market Research Report
By Type
ARD-3150, Ciprofloxacin Hydrochloride, EV-035, NDBR-101, Others
By Application
Hospital, Clinic, Others
By Companies
Aradigm Corp, Arno Therapeutics Inc, DynPort Vaccine Company LLC, Emergent BioSolutions Inc, EpiVax Inc, Grifols SA, Merck & Co Inc, Tetraphase Pharmaceuticals Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Tularaemia Treatment Market Report Segments:
The global Tularaemia Treatment market is segmented on the basis of:
Types
ARD-3150, Ciprofloxacin Hydrochloride, EV-035, NDBR-101, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Aradigm Corp
- Arno Therapeutics Inc
- DynPort Vaccine Company LLC
- Emergent BioSolutions Inc
- EpiVax Inc
- Grifols SA
- Merck & Co Inc
- Tetraphase Pharmaceuticals Inc
Highlights of The Tularaemia Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ARD-3150
- Ciprofloxacin Hydrochloride
- EV-035
- NDBR-101
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tularaemia Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tularaemia is a blood infection caused by the protozoan parasite Tularaemia tularensis. Treatment typically involves antibiotics and, in some cases, surgery to remove the infected organ.
Some of the key players operating in the tularaemia treatment market are Aradigm Corp, Arno Therapeutics Inc, DynPort Vaccine Company LLC, Emergent BioSolutions Inc, EpiVax Inc, Grifols SA, Merck & Co Inc, Tetraphase Pharmaceuticals Inc.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Tularaemia Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Tularaemia Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Tularaemia Treatment Market - Supply Chain
4.5. Global Tularaemia Treatment Market Forecast
4.5.1. Tularaemia Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Tularaemia Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Tularaemia Treatment Market Absolute $ Opportunity
5. Global Tularaemia Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Tularaemia Treatment Market Size and Volume Forecast by Type
5.3.1. ARD-3150
5.3.2. Ciprofloxacin Hydrochloride
5.3.3. EV-035
5.3.4. NDBR-101
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Tularaemia Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Tularaemia Treatment Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Tularaemia Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Tularaemia Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Tularaemia Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Tularaemia Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Tularaemia Treatment Demand Share Forecast, 2019-2026
9. North America Tularaemia Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Tularaemia Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Tularaemia Treatment Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Tularaemia Treatment Market Size and Volume Forecast by Type
9.7.1. ARD-3150
9.7.2. Ciprofloxacin Hydrochloride
9.7.3. EV-035
9.7.4. NDBR-101
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Tularaemia Treatment Demand Share Forecast, 2019-2026
10. Latin America Tularaemia Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Tularaemia Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Tularaemia Treatment Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Tularaemia Treatment Market Size and Volume Forecast by Type
10.7.1. ARD-3150
10.7.2. Ciprofloxacin Hydrochloride
10.7.3. EV-035
10.7.4. NDBR-101
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Tularaemia Treatment Demand Share Forecast, 2019-2026
11. Europe Tularaemia Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Tularaemia Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Tularaemia Treatment Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Tularaemia Treatment Market Size and Volume Forecast by Type
11.7.1. ARD-3150
11.7.2. Ciprofloxacin Hydrochloride
11.7.3. EV-035
11.7.4. NDBR-101
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth rojections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Tularaemia Treatment Demand Share, 2019-2026
12. Asia Pacific Tularaemia Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Tularaemia Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Tularaemia Treatment Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Tularaemia Treatment Market Size and Volume Forecast by Type
12.7.1. ARD-3150
12.7.2. Ciprofloxacin Hydrochloride
12.7.3. EV-035
12.7.4. NDBR-101
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Tularaemia Treatment Demand Share, 2019-2026
13. Middle East & Africa Tularaemia Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Tularaemia Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Tularaemia Treatment Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Tularaemia Treatment Market Size and Volume Forecast by Type
13.7.1. ARD-3150
13.7.2. Ciprofloxacin Hydrochloride
13.7.3. EV-035
13.7.4. NDBR-101
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Tularaemia Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Tularaemia Treatment Market: Market Share Analysis
14.2. Tularaemia Treatment Distributors and Customers
14.3. Tularaemia Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Aradigm Corp
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Arno Therapeutics Inc
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. DynPort Vaccine Company LLC
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Emergent BioSolutions Inc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. EpiVax Inc
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Grifols SA
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Merck & Co Inc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Tetraphase Pharmaceuticals Inc
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
